近日，鱼跃医疗发布2025年三季度报告，今年前三季度，公司实现营业收入65.45亿元，同比增长 8.58%；其中第三季度实现营业收入18.86亿元，同比增长9.63%。鱼跃医疗表示，通过产品技术突破、 拓宽销售渠道、增强品牌影响力等多方面努力，糖尿病护理解决方案板块成为公司日趋重要的新增长 极。 持续加大研发投入，持续血糖监测系列产品放量 随着我国糖尿病患病率的快速增长，血糖与体重管理逐渐成为慢病预防、提高生活质量的重要措施。在 今年全国两会上，国家卫生健康委宣布持续实施"体重管理年"3年行动，引发社会热议，带动健康消费 市场持续火爆。越来越多人开始重视体重，追求健康饮食控制、营养补充等良好的生活方式和习惯。中 新经纬研究院发布的《"618"消费洞察报告（2024）》显示，家庭诊疗仪器品类涨势惊人，其中血糖类 产品增长超过了40%。 作为家用医疗器械龙头企业，鱼跃医疗血糖管理业务近两年持续维持两位数的高速增长态势，其中 CGM（持续血糖监测系统）系列产品作为近年来公司大力推动的业务板块，可连续24小时动态监测血 糖波动，具备舒适性、便捷性、安全性、智能化等优势，成为血糖管理领域的前沿技术产品。目前国内 市场对 ...

Core Viewpoint - Yuyue Medical, a leading home medical device company, reported a revenue of 6.545 billion yuan for the first three quarters of 2023, marking an 8.58% year-on-year increase, and announced its first-ever third-quarter dividend since listing, reflecting strong financial performance and commitment to shareholder returns [1] Financial Performance - For the first three quarters of 2023, Yuyue Medical achieved an operating income of 6.545 billion yuan, up 8.58% year-on-year, and a net operating cash flow of 1.504 billion yuan, increasing by 8.77% [1] - In Q3 2023, the company reported an operating income of 1.886 billion yuan, representing a 9.63% year-on-year growth [1] - The total dividend after this distribution will reach 4.959 billion yuan [1] R&D and Product Development - Yuyue Medical has significantly increased its R&D investment, reaching 444.5 million yuan in the first three quarters of 2023, a 9.76% increase year-on-year, positioning it among the top four listed medical device companies in China [2] - The company’s gross margin improved to 50.35%, driven by the introduction of high-end products and continuous innovation [2] - The blood glucose management and POCT solutions segment has maintained double-digit growth since 2022, showcasing the successful transformation of R&D efforts into marketable products [2] Product Launch and Market Performance - The new CGM products, Anytime 4 and Anytime 5 series, launched in 2025, have shown significant advancements in usability, battery life, and measurement accuracy, achieving an 8.58% MARD value [2] - The mobile app "Yuyue Anai Sugar" has seen a rapid increase in downloads, ranking first in the wearable device category on Apple's App Store since June [3] - During the 618 shopping festival, the new product series achieved a 165% sales growth on JD.com, contributing to the rapid popularization of CGM products in the domestic market [3] Strategic Initiatives - The company is focusing on enhancing R&D and brand building, particularly in digital and wearable products, to increase market share in CGM products [3] - Yuyue Medical has launched the AI Health Steward application, integrating data from various medical devices for health data management and analysis [3][4] - The company is actively pursuing an internationalization strategy, establishing subsidiaries in key markets like Germany, Thailand, and the USA, and recently launched a subsidiary in Indonesia to strengthen its presence in Southeast Asia [5][6] Market Trends and Future Outlook - The rise of AI technology is expected to inject new vitality into chronic disease management, with companies that integrate data, algorithms, and ecosystems likely to dominate the market [4] - Yuyue Medical aims to redefine blood glucose management through the deep integration of AI and CGM technologies, leveraging nearly 30 years of expertise in the medical device field [4] - The company is committed to a long-term strategy focused on AI technology and global expansion, as emphasized by its chairman [7]